ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer.

Autor:	Galicia-Carmona T; Department of Clinical Research, Instituto Nacional De Cancerología, Mexico City, Mexico.; Department of Medical Oncology, Instituto Nacional De Cancerología, Mexico City, Mexico., Arango-Bravo E; Department of Clinical Research, Instituto Nacional De Cancerología, Mexico City, Mexico.; Department of Medical Oncology, Instituto Nacional De Cancerología, Mexico City, Mexico., Serrano-Olvera JA; Department of Medical Oncology, Centro Médico ABC, Mexico City, Mexico., Flores-de La Torre C; Department of Medical Oncology, Centro Estatal De Oncología Campeche INDESALUD, Campeche, Mexico., Cruz-Esquivel I; Department of Surgical Oncology, Centro Estatal De Oncología Campeche INDESALUD, Campeche, Mexico., Villalobos-Valencia R; Oncology Hospital, Centro Médico Siglo XXI, Instituto Mexicano Del Seguro Social (IMSS), Mexico City, Mexico., Morán-Mendoza A; Department of Oncology, UMAE Hospital Ginecoobstetricia, Centro Médico Nacional De Occidente, Instituto Mexicano Del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico., Castro-Eguiluz D; Instituto Nacional De Cancerología, Mexico City, Mexico., Cetina-Pérez L; Department of Clinical Research, Instituto Nacional De Cancerología, Mexico City, Mexico.; Department of Medical Oncology, Instituto Nacional De Cancerología, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Aug 03; Vol. 17 (8), pp. 2617-2625. Date of Electronic Publication: 2021 Apr 01.
DOI:	10.1080/21645515.2021.1893036
Abstrakt:	Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated Listeria monocytogenes -listeriolysin O ( Lm -LLO), designed by biological engineering to secrete an antigen-adjuvant fusion protein, composed of a truncated fragment of LLO fused to HPV. The proposed mechanism of action is that Lm -based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I-II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu